WEKO3
アイテム
{"_buckets": {"deposit": "ffda9474-7a5c-4af3-81e5-a12463fa17f3"}, "_deposit": {"created_by": 2, "id": "22006", "owners": [2], "pid": {"revision_id": 0, "type": "depid", "value": "22006"}, "status": "published"}, "_oai": {"id": "oai:nagasaki-u.repo.nii.ac.jp:00022006", "sets": ["1563"]}, "author_link": ["93924"], "item_3_biblio_info_6": {"attribute_name": "書誌情報", "attribute_value_mlt": [{"bibliographicIssueDates": {"bibliographicIssueDate": "1993-12-25", "bibliographicIssueDateType": "Issued"}, "bibliographicIssueNumber": "2-4", "bibliographicPageEnd": "78", "bibliographicPageStart": "74", "bibliographicVolumeNumber": "38", "bibliographic_titles": [{"bibliographic_title": "Acta medica Nagasakiensia"}]}]}, "item_3_description_4": {"attribute_name": "抄録", "attribute_value_mlt": [{"subitem_description": "Proliferating cell nuclear antigen (PCNA) is an auxiliary protein of DNA polymerase-∂ that is synthesized during the late G1 phase through the S phase of cell proliferation. The expression of PCNA correlates strongly with cell proliferation. In the present study, employing NC-012, which is an anti-human PCNA monoclonal antibody, we performed immunohistochemical staining on specimens obtained from 71 new prostatic carcinoma patients by needle biopsy. We analyzed the results of PCNA immunoreactivity for correlation with the prognosis of the patients. The positive staining rate was 0~11.4% for prostatic carcinoma, while it was 0~2.6% in 10 cases of benign prostatic hypertrophy. The PCNA-positive rate tended to be high in cases of moderately to poorly differentiated prostatic carcinoma, but it was not significant. With regard to the prognosis, it was found that the prognosis tended to be worse in the PCNA- positive cases compared with the PCNA-negative cases. Further, multivariate survival analysis of six parameters (i. e., the patient\u0027s age, histological grade, clinical stage, serum prostatic acid phosphatase, initial treatment and the PCNA-positive rate) revealed that the clinical stage, histological grade and the PCNA-positive rate were the first, second and third most significant prognostic parameters, respectively.", "subitem_description_type": "Abstract"}]}, "item_3_description_64": {"attribute_name": "引用", "attribute_value_mlt": [{"subitem_description": "Acta medica Nagasakiensia. 1993, 38(2-4), p.74-78", "subitem_description_type": "Other"}]}, "item_3_source_id_10": {"attribute_name": "書誌レコードID", "attribute_value_mlt": [{"subitem_source_identifier": "AA00508430", "subitem_source_identifier_type": "NCID"}]}, "item_3_source_id_7": {"attribute_name": "ISSN", "attribute_value_mlt": [{"subitem_source_identifier": "00016055", "subitem_source_identifier_type": "ISSN"}]}, "item_3_text_62": {"attribute_name": "sortkey", "attribute_value_mlt": [{"subitem_text_value": "P00074-P00078"}]}, "item_3_version_type_16": {"attribute_name": "著者版フラグ", "attribute_value_mlt": [{"subitem_version_resource": "http://purl.org/coar/version/c_970fb48d4fbd8a85", "subitem_version_type": "VoR"}]}, "item_creator": {"attribute_name": "著者", "attribute_type": "creator", "attribute_value_mlt": [{"creatorNames": [{"creatorName": "Shiraishi, Kazutaka"}], "nameIdentifiers": [{"nameIdentifier": "93924", "nameIdentifierScheme": "WEKO"}]}]}, "item_files": {"attribute_name": "ファイル情報", "attribute_type": "file", "attribute_value_mlt": [{"accessrole": "open_date", "date": [{"dateType": "Available", "dateValue": "2020-12-23"}], "displaytype": "detail", "download_preview_message": "", "file_order": 0, "filename": "acta38_02_08_t.pdf", "filesize": [{"value": "709.2 kB"}], "format": "application/pdf", "future_date_message": "", "is_thumbnail": false, "licensetype": "license_free", "mimetype": "application/pdf", "size": 709200.0, "url": {"label": "acta38_02_08_t.pdf", "url": "https://nagasaki-u.repo.nii.ac.jp/record/22006/files/acta38_02_08_t.pdf"}, "version_id": "9ed4cb0a-e156-48c1-b8f3-efc9b33c9ed2"}]}, "item_language": {"attribute_name": "言語", "attribute_value_mlt": [{"subitem_language": "eng"}]}, "item_resource_type": {"attribute_name": "資源タイプ", "attribute_value_mlt": [{"resourcetype": "departmental bulletin paper", "resourceuri": "http://purl.org/coar/resource_type/c_6501"}]}, "item_title": "Proliferating Cell Nuclear Antigen (PCNA) in Prostatic Carcinoma", "item_titles": {"attribute_name": "タイトル", "attribute_value_mlt": [{"subitem_title": "Proliferating Cell Nuclear Antigen (PCNA) in Prostatic Carcinoma"}]}, "item_type_id": "3", "owner": "2", "path": ["1563"], "permalink_uri": "http://hdl.handle.net/10069/15911", "pubdate": {"attribute_name": "公開日", "attribute_value": "2008-03-13"}, "publish_date": "2008-03-13", "publish_status": "0", "recid": "22006", "relation": {}, "relation_version_is_last": true, "title": ["Proliferating Cell Nuclear Antigen (PCNA) in Prostatic Carcinoma"], "weko_shared_id": -1}
Proliferating Cell Nuclear Antigen (PCNA) in Prostatic Carcinoma
http://hdl.handle.net/10069/15911
http://hdl.handle.net/10069/1591113e2f04c-00b4-4dbe-a19b-cda99b198707
名前 / ファイル | ライセンス | アクション |
---|---|---|
acta38_02_08_t.pdf (709.2 kB)
|
|
Item type | 紀要論文 / Departmental Bulletin Paper(1) | |||||
---|---|---|---|---|---|---|
公開日 | 2008-03-13 | |||||
タイトル | ||||||
タイトル | Proliferating Cell Nuclear Antigen (PCNA) in Prostatic Carcinoma | |||||
言語 | ||||||
言語 | eng | |||||
資源タイプ | ||||||
資源タイプ識別子 | http://purl.org/coar/resource_type/c_6501 | |||||
資源タイプ | departmental bulletin paper | |||||
著者 |
Shiraishi, Kazutaka
× Shiraishi, Kazutaka |
|||||
抄録 | ||||||
内容記述タイプ | Abstract | |||||
内容記述 | Proliferating cell nuclear antigen (PCNA) is an auxiliary protein of DNA polymerase-∂ that is synthesized during the late G1 phase through the S phase of cell proliferation. The expression of PCNA correlates strongly with cell proliferation. In the present study, employing NC-012, which is an anti-human PCNA monoclonal antibody, we performed immunohistochemical staining on specimens obtained from 71 new prostatic carcinoma patients by needle biopsy. We analyzed the results of PCNA immunoreactivity for correlation with the prognosis of the patients. The positive staining rate was 0~11.4% for prostatic carcinoma, while it was 0~2.6% in 10 cases of benign prostatic hypertrophy. The PCNA-positive rate tended to be high in cases of moderately to poorly differentiated prostatic carcinoma, but it was not significant. With regard to the prognosis, it was found that the prognosis tended to be worse in the PCNA- positive cases compared with the PCNA-negative cases. Further, multivariate survival analysis of six parameters (i. e., the patient's age, histological grade, clinical stage, serum prostatic acid phosphatase, initial treatment and the PCNA-positive rate) revealed that the clinical stage, histological grade and the PCNA-positive rate were the first, second and third most significant prognostic parameters, respectively. | |||||
書誌情報 |
Acta medica Nagasakiensia 巻 38, 号 2-4, p. 74-78, 発行日 1993-12-25 |
|||||
ISSN | ||||||
収録物識別子タイプ | ISSN | |||||
収録物識別子 | 00016055 | |||||
書誌レコードID | ||||||
収録物識別子タイプ | NCID | |||||
収録物識別子 | AA00508430 | |||||
著者版フラグ | ||||||
出版タイプ | VoR | |||||
出版タイプResource | http://purl.org/coar/version/c_970fb48d4fbd8a85 | |||||
sortkey | ||||||
P00074-P00078 | ||||||
引用 | ||||||
内容記述タイプ | Other | |||||
内容記述 | Acta medica Nagasakiensia. 1993, 38(2-4), p.74-78 |